Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of dis...
Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance...
IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world's largest pharm...
Bayer announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer...
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. Critical...
Hillhurst Biopharmaceuticals Inc. ("Hillhurst Bio"), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products bas...
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) progra...
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), underscored its industry leadership in the dev...
ZoBio, a boutique problem-solving Contract Research Organization (CRO) specializing in early gene-to-lead discovery, today announced the launch of its co...
Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advanci...
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to ...
As a strategic step to better support growing demand and strengthen future service capacity, Quintara Biosciences announced that its Boston area laboratory...
Volta Labs, the genomics applications company transforming next-generation sequencing (NGS) sample preparation through automation, announced the launch o...
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment ...
© 2026 Biopharma Boardroom. All Rights Reserved.
